Thyrocare Technologies, the pathology chain majority-owned by PharmEasy, has approved the sale of its entire stake in radiology subsidiary Nueclear Healthcare to Trovera Healthcare for roughly ₹141.4 crore. The board cleared the deal on September 21, and it marks Thyrocare's complete exit from the radiology and diagnostic imaging business.
The structure is the interesting part Thyrocare isn't just taking a cheque. Of the total consideration, ₹81.9 crore comes as cash and the remaining ₹59.5 crore as preference shares in Trovera itself, giving Thyrocare a small, ongoing stake roughly 4.5% in the very company it's selling to.
This is less an exit than a strategic handoff: Thyrocare is shedding a capital-heavy business while quietly keeping a toehold in it, at a moment when PharmEasy's broader portfolio is under visible restructuring pressure.
The Details
- Seller: Thyrocare Technologies (PharmEasy-owned)
- Buyer: Trovera Healthcare Pvt Ltd
- Asset sold: 100% stake in Nueclear Healthcare Ltd (1,11,11,000 equity shares)
- Total consideration: ~₹141.4 crore
- Cash component: ₹81.9 crore (subject to working capital adjustment)
- Non-cash component: ₹59.5 crore via 42,500 CCPS of Trovera at ₹14,000/share (~4.5% of Trovera, fully diluted)
- Separate transaction: Thyrocare buys back Gurugram & Hyderabad lab properties from Nueclear for ₹20.59 crore
- Board rights: Thyrocare can nominate up to 3 directors on Trovera's board
- Target closing: November 30, 2026, pending shareholder and regulatory approval
Why Sell a Business That's Still Profitable
Nueclear wasn't dead weight. It contributed ₹44.62 crore in FY26 revenue about 5.38% of Thyrocare's consolidated turnover.
Its net worth stood at ₹83.55 crore, roughly 14.27% of Thyrocare's total net worth. That's a meaningful slice of the balance sheet to let go of.
The stated reason is capital discipline. Radiology needs continuous reinvestment in equipment, imaging tech and infrastructure money pathology testing doesn't demand at the same pace.
At ₹141.4 crore against ₹83.55 crore net worth, Thyrocare is selling at roughly 1.7x book value a reasonable, not spectacular, premium for a business it no longer wants to fund.
Buying Back the Buildings It Just Sold
Here's the detail easy to miss: Thyrocare is simultaneously buying back the Gurugram and Hyderabad lab properties it's selling, for ₹20.59 crore.
These are premises Thyrocare currently leases from Nueclear to run its own diagnostic labs.
By owning them outright, Thyrocare avoids future lease costs and any disruption risk from a new landlord post-divestment a clean way to de-risk the exit.
What the Numbers Don't Tell You
Taking equity in the buyer is a classic move when a seller wants exposure to a business's future without owning its operational burden but it also means Thyrocare's "clean exit" isn't fully clean.
If Trovera's radiology bet works, Thyrocare benefits through its CCPS. If it doesn't, that 4.5% stake could become a write-off sitting quietly on the balance sheet.
The larger context matters too: this is another asset-shedding move inside a PharmEasy-linked entity, at a time when the group's broader portfolio has faced scrutiny over debt and restructuring. One divestment doesn't confirm a pattern, but it's worth watching whether more follow.
The Bottom Line
Watch whether Trovera keeps sending referrals back to Thyrocare's pathology business that relationship, more than the ₹141 crore, will decide if this was a smart trim or a strategic retreat.
